pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Small Molecule · news · pharmadog
← back to Small Molecule
News · Small Molecule
292
stories
15d
Lilly climbs, Novo falls as obesity drug battle intensifies
biopharma dive
15d
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
biopharma dive
15d
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
biospace
15d
Novo CEO sees innovation as a matter of survival amid pipeline setbacks
biospace
15d
Fecal transplant increases tolerance to peanuts sixfold in small food allergy trial
fiercebiotech
15d
‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
fiercebiotech
15d
5 NextGen winners who went public this year (and which ones are hiring)
biospace
16d
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
16d
Novo dips 6% on Wegovy pill stumble despite Q2 earnings beat
biospace
16d
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
biospace
16d
Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
biospace
16d
Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
fiercebiotech
16d
Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
fiercebiotech
17d
Supernus, Indivior merge to beef up brain drug portfolio
biopharma dive
17d
Novo’s late-stage IL-6 stumble shakes inflammation space
biospace
18d
5 companies advancing ATTR assets in the wake of Wainua’s fail
biospace
20d
Resilience and Lilly invest $750M to boost Cincinnati drug production
biopharma dive
20d
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
20d
Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
biospace
20d
Syphilis spreads while researchers contend with federal constraints and a drug shortage
stat
21d
Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
fiercebiotech
21d
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
biospace
21d
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
biospace
21d
BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
fiercebiotech
21d
Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs
fiercebiotech
21d
Opinion: Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases
stat
21d
New funding, new jobs: 4 biotechs hiring after series B raises
biospace
22d
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech
22d
STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx
stat
22d
Private biotechs Caldera and Vidya raise $478M collectively in reverse go-public mergers
biospace
← prev
page 3 of 10
next →
